The QualityStocks Daily Monday, May 4th, 2020

Today's Top 3 Investment Newsletters

StockMarketWatch (STML) +154.84%

BUYINS.NET (MVIS) +147.58%

QualityStocks (GFIOF) +83.37%

The QualityStocks Daily Stock List

American Creek Resources Ltd. (ACKRF)

Junior Mining Network, hot Stocked, MineStat, Gold Telegraph, Stockhouse, Morningstar, Investing Online, Equities, GuruFocus, Seeking Alpha, InvestorsHub, All Stocks Today, Resource World, OTC Markets, Barchart, Wallet Investor, Gold Stock Data, Dividend Investor, Mining News Feed, and TradingView reported previously on American Creek Resources Ltd. (ACKRF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

American Creek Resources Ltd. is a mineral exploration company with a strong portfolio of gold and silver properties in the Province of British Columbia. The Company has high quality assets in significant mineral belts of British Columbia (B.C.), close to infrastructure. These include properties in B.C.'s prolific Golden Triangle, one of the richest areas of mineralization in the world. Founded in 2004, American Creek Resources is based in Cardston, Alberta.

Three of the Company’s properties are located in the prolific "Golden Triangle"; the Treaty Creek and Electrum joint venture (JV) projects with Tudor Gold/Walter Storm and also the 100 percent owned past producing Dunwell Mine. An exploration program is continuing on the Company's Dunwell Mine property situated near Stewart. Furthermore, American Creek holds the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King properties situated in other prospective areas of the Province.

In April, American Creek Resources reported that its JV partner Tudor Gold Corp. started metallurgical studies for the JV flagship project, Treaty Creek, located in the Golden Triangle. The study will focus on the mineral characteristics and the prospects of developing Treaty Creek as a bulk tonnage mining target using conventional processing techniques. The test work will be conducted on material selected from the extensive continuously mineralized drill core intervals encountered in last year’s exploration program. The metallurgical test results will be used as part of the initial economic assessment for the project.

The Treaty Creek Project is a JV with Tudor Gold owning 3/5th and acting as operator. American Creek Resources and Teuton Resources each have a 1/5th interest in the project creating a 3:1 ownership relationship between Tudor Gold and American Creek. American Creek and Teuton are both fully carried until such time as a Production Notice is issued. At that they are required to contribute their respective 20 percent share of development costs. Until such time, Tudor Gold is required to fund all exploration and development costs while American Creek Resources and Teuton Resources have "free rides".

American Creek Resources Ltd. (ACKRF), closed Monday's trading session at $0.0547, up 5.1923%, on 300 volume with 3 trades. The average volume for the last 3 months is 53,322 and the stock's 52-week low/high is $0.016/$0.086000002.

chart

Balmoral Resources Ltd. (BALMF)

OTC Markets, Mining.com, GlobeNewswire, Northern Miner, Metals News, ABN Newswire, Equedia, Investing.com, Mining Feeds, Streetwise Reports, Wallet Investor, Proactive Investors, InvestorsHub, Mining Atlas, Junior Mining Network, News Scanner, Dividend Investor, Resource World, Stockhouse, Trading View, and Investing News reported beforehand on Balmoral Resources Ltd. (BALMF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Balmoral Resources Ltd. is an exploration company exploring a portfolio of gold and base metal properties positioned within the prolific Abitibi greenstone belt. The Company’s flagship, 1,000 km2 Detour Gold Trend Project hosts the resource-stage Bug and Martiniere West gold deposits and the Grasset nickel-copper-cobalt-PGE deposit. Balmoral is led by an experienced and successful Board of Directors and Management team with a lengthy track record of creating shareholder value via the exploration process. Balmoral Resources is headquartered in Vancouver, British Columbia. The Company lists on the OTC Market Group’s OTCQX.

Balmoral has dual exposure to the gold and nickel sulphide markets. Its gold projects comprise Martiniere, Northshore, N2, Lynx-Rambo, Lac Du Doight, Grasset Gold, Area 52 (Fenelon), Detour Trend, and Vortex Ext. The Company’s nickel projects comprise Grasset, GUC Central, Gargoyle, RUM, Goblin, and Ghost.

Grasset is a Nickel-Copper-Cobalt- PGE Deposit. It is the most advanced of the nickel discoveries made by Balmoral Resources in the Grasset Ultramafic Complex. The Project is 100 percent owned by Balmoral - royalty free.

The Grasset Nickel Deposit features some of the highest tenor (nickel content) sulphides in Canada. This allows it to produce very high nickel grades. Balmoral previously announced more discoveries within the Grasset Ultramafic Complex 7 km to the NW. At the Grasset Nickel Deposit, nickel, copper, cobalt, platinum and palladium are all considered recoverable and payable.

Last week, Balmoral Resources announced a new, very high-grade gold discovery on its Fenelon Property in the Province of Quebec. The Reaper gold discovery returned an intercept of 858.00 g/t gold over 1.06 meters, as part of a wider 2.97 meter wide mineralized zone grading 307.89 g/t gold. The Reaper discovery occurs along the western margin of the Area 51 intrusion on the southern part (Area 52 segment) of Balmoral’s Fenelon Property.

Wallbridge Mining Company Limited’s high grade Tabasco Zone occurs along the eastern margin of the same intrusion on the adjacent Fenelon Mine Property. Balmoral Resources’ Fenelon Property forms part of the Company’s district-scale Detour Gold Trend Project in Quebec.

Balmoral Resources Ltd. (BALMF), closed Monday's trading session at $0.4452, up 19.0374%, on 659,278 volume with 173 trades. The average volume for the last 3 months is 274,643 and the stock's 52-week low/high is $0.065700002/$0.460000008.

chart
n

Five Prime Therapeutics, Inc. (FPRX)

Zacks, Enterprise Echo, Nasdaq BioInvest, Investors Observer, Street Insider, Equities.com, Markets Insider, Investing.com, Market Chameleon, StockInvest.us, StockNews, InvestorsHub, Stocktwits, BioPharmCatalyst, FierceBiotech, Simply Wall St, Morningstar, Seeking Alpha, MacroTrends, YCharts, and Dividend Investor reported beforehand on Five Prime Therapeutics, Inc. (FPRX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Five Prime Therapeutics, Inc. is developing novel immuno-oncology protein therapeutics. The Company is working to develop immune modulators and precision therapies for solid tumor cancers. Its product candidates have innovative mechanisms of action and address patient populations in need of better therapies. A clinical-stage biotechnology company and Nasdaq-listed, Five Prime Therapeutics is based in South San Francisco, California.

The Company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with its product candidates. Five Prime Therapeutics has entered into strategic collaborations with leading global pharmaceutical companies. The Company has promising product candidates in clinical and preclinical development.

Five Prime Therapeutics programs include Bemarituzumab - FGFR2B Antibody - FIGHT trial (with chemo) in 1L gastric/GEJ cancer; and FPA150 B7-H4 Antibody - Breast, ovarian and endometrial cancers. Programs also include FPT155 - CD80-FC Fusion - Multiple tumor settings; and I-O Antibodies - Multiple tumor settings.

Bemarituzumab (anti-FGFR2b) is a first-in-class isoform-selective antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) in development as a targeted immunotherapy for tumors that overexpress FGFR2b. Bemarituzumab is undergoing evaluation in combination with mFOLFOX6 in the Phase 3 FIGHT (FGFR2b Inhibition in Gastric and Gastroesophageal Junction Cancer Treatment) trial. Five Prime Therapeutics has paused enrollment in the FIGHT trial pending the occurrence of a sufficient number of events to trigger a futility analysis, expected to occur in mid-2020.

This past March, Five Prime Therapeutics announced the publication of results from the Phase 1 escalation and expansion study of bemarituzumab in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma in the digital edition of the Journal of Clinical Oncology. Phase 1 data illustrates the therapeutic potential of bemarituzumab as a novel approach to treating patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).

Five Prime Therapeutics will report its Q1 2020 operational and financial results on Thursday, May 7, 2020 after the U.S. financial markets close. In addition, the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 4:30 p.m. (ET) / 1:30 p.m. (PT) to provide a general business update and discuss its financial results.

Five Prime Therapeutics, Inc. (FPRX), closed Monday's trading session at $3.225, up 11.2069%, on 153,570 volume with 1,440 trades. The average volume for the last 3 months is 360,763 and the stock's 52-week low/high is $1.75/$11.6800003.

chart

Harvest Oil & Gas Corp. (HRST)

TipRanks, EnergyNow.com, MarketWatch, Nasdaq, Real Investment Advice, OilBlockChain.News, OTC Markets, Dividend.com, OilandGas360, last10k, TradingView, Investing.com, YCharts, GuruFocus, GlobeNewswire, Barchart, Simply Wall St, Wallet Investor, Dividend Investor, Market Screener, and Stockwatch reported earlier on Harvest Oil & Gas Corp. (HRST), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Harvest Oil & Gas Corp. is an independent oil and natural gas company with its head office in Houston, Texas. It engages in the development and production of oil and natural gas properties in the United States. On June 4, 2018, EV Energy Partners, L.P., successfully completed its financial restructuring and emerged from Chapter 11 of the U.S. Bankruptcy Code as Harvest Oil & Gas Corp. Established in 2006, Harvest Oil & Gas lists on the OTC Markets Group’s OTCQX.

The Company’s assets consist primarily of producing and non-producing properties in the Barnett Shale, the Appalachian Basin (includes the Utica Shale), Michigan, the Mid-Continent areas in Oklahoma, Texas, Kansas and Louisiana, the Permian Basin, and the Monroe Field in Northern Louisiana.

Harvest Oil & Gas’ oil and natural gas properties include 545 Bcfe of estimated net proved reserves located in Kansas, Louisiana, Michigan, New Mexico, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Since January of 2019, the Company sold all interests in the San Juan Basin representing 157.6 Bcfe and certain interests in the Mid-Continent area representing 9.5 Bcfe.

In April, Harvest Oil & Gas announced results for Q4 and full year 2019. Average daily production was 53.1 MMcfe for Q4 of 2019. In December 2019, it closed on the sale of substantially all of its remaining oil and natural gas properties in the Barnett Shale for $6.2 million, net of preliminary purchase price adjustments.

In December 2019, the Company closed on the sale of substantially all of Harvest’s oil and natural gas properties in the Permian Basin for total consideration of $2.9 million, net of purchase price adjustments. It expects a subsequent closing for total consideration of $0.1 million in Q2 of 2020, subject to customary purchase price adjustments.

In March 2020, Harvest Oil & Gas signed a purchase and sale agreement to sell all of its oil and natural gas properties in Michigan for a purchase price of $4.8 million, subject to an adjustment based on the value of certain derivative contracts and other customary purchase price adjustments. The expected closing is during Q2 of 2020.

Harvest Oil & Gas continues to review strategic alternatives following the divestiture of significant assets during 2019. It is actively considering the potential divestiture of all of its remaining assets and also a potential sale or merger of the Company.

Harvest Oil & Gas Corp. (HRST), closed Monday's trading session at $2.40, up 16.5049%, on 1,759 volume with 17 trades. The average volume for the last 3 months is 41,545 and the stock's 52-week low/high is $1.75/$17.25.

chart

Item 9 Labs Corp. (INLB)

OTC Markets, last10k, Real Investment Advice, CannabisMarketCap, Financial Buzz, Invest Tribune, TradingView, Dividend Investor, Pot Stock News, Investors Hangout, TipRanks, Market Screener, Stockwatch, Financial Content, Stockhouse, Wallet Investor, GlobeNewswire, EIN Presswire, GuruFocus, Equity Clock, Business Insider, and InvestorsHub reported previously on Item 9 Labs Corp. (INLB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Item 9 Labs Corp. is a leader in comfortable cannabis health solutions for the modern consumer. The Company is bringing best of industry practices to markets across the nation through cultivation and production, distinct retail environments, licensing services, and diverse product suites. It caters to various medical cannabis demographics. The Company’s intention is to manage cultivation, processing, distribution, and dispensary operations in up to ten U.S. markets by the end of 2020. Item 9 Labs has its head office in Phoenix, Arizona. Additionally, it has medical cannabis operations in manifold U.S. markets.

Item 9 Labs’ asset portfolio includes Dispensary Permits, Dispensary Templates, and Strive Life. Dispensary Permits is its consulting firm. It specializes in strategic license application and compliance.

Dispensary Templates, a subdivision of the Company, is a technology platform with an extensive digital library of licensing and business planning resources. Strive Life is a turnkey dispensary model for the retail sector. It improves the patient experience with consistent and premier service, high-end design, and precision-tested products.

Item 9 Labs has also created complementary brands - Item 9 Labs and Strive Wellness - to channel consumer diversity. Propriety delivery platforms include the Apollo Vape and Pod system, and a leading-edge intra-nasal device. The Company has received many accolades for its medical-grade flower and concentrates. Its facilities include distribution and processing operations - Strive Wellness of Ohio and Strive Wellness of Nevada, and a dispensary - Strive Life North Dakota.

Item 9 Labs announced in December 2019 a joint venture (JV) with Third Eye Investments (Phoenix-Based). This JV is to expand into the CBD (cannabidiol) extraction and hemp consumer goods market. This partnership will focus on the development of Spectrum 8 hemp with planned nationwide distribution and construction of the first solvent free, RF processing extraction facility in North America.

Last week, Item 9 Labs announced product demand and revenue growth exceeding projections despite the continuing COVID-19 pandemic. The Company has seen a 43 percent sales increase in 2020 versus year-over-year to January through March 2019. March 2020 brought a 117percent sales increase versus March 2019 - with the entire Arizona Medical Marijuana Program reporting a 32 percent year-over-year increase in total product sold.

Item 9 Labs Corp. (INLB), closed Monday's trading session at $0.85, up 2.4096%, on 3,765 volume with 4 trades. The average volume for the last 3 months is 4,308 and the stock's 52-week low/high is $0.699999988/$5.98999977.

chart

Major Drilling Group International, Inc. (MJDLF)

Northern Miner, 24hgold, Street Insider, Nasdaq, Macroaxis, Market Screener, Invest Tribune, Seeking Alpha, MarketBeat, Capital Cube, Wallmine, 4-Traders, Wallet Investor, YCharts, GuruFocus, Dividend Investor, Stockhouse, MarketWatch, and Morningstar reported earlier on Major Drilling Group International, Inc. (MJDLF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Major Drilling Group International, Inc. provides contract drilling services for mining and mineral exploration companies in the USA, Canada, Mexico, South America, Asia, Africa, and Europe. The Company has a fleet of approximately 601 drilling rigs. Major Drilling Group is one of the world’s largest drilling services companies chiefly serving the mining industry. Established in 1980, the Company is based in Moncton, New Brunswick.

Major Drilling Group is registered in greater than 20 countries on 6 continents. Its Senior Management has more than 1,000 years of combined experience. Concerning the emergence of “Specialized Drilling” Major Drilling Group’s business premise is that the new deposits over the next 20 years will be in areas difficult to access and that specialized drilling will be a greater part of the market.

The Company offers a suite of drilling services. These include surface and underground coring, directional, reverse circulation, sonic, geotechnical, environmental, water-well, coal-bed methane, shallow gas, underground percussive/longhole drilling, surface drill and blast, and different mine services.

Major Drilling Group offers services including mineral exploration, directional drilling, definition or infield drilling, mine development, dewatering, grade control, and percussive drilling for a producing mine. Its environmental and sonic group can help sample tailings piles, monitor tailings dams, install grout curtains, and also install ground water sampling wells.

In late January of this year, Major Drilling Group International announced the achievement of the longest diamond drill hole in Canada at the Osisko Mining, Inc. Discovery 1 project. The final length of Discovery 1 was 3,467 meters.

This past February, Major Drilling Group International reported results for its Q3 of fiscal year 2020, ended January 31, 2020. Quarterly revenue was $81.7 million, up 2 percent from the same quarter last year. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was relatively flat at $2.7 million for the quarter versus the same period last year.

Net Loss included $3.6 million of charges ($3.0 million non-cash) related to the closure of the Colombian operations. Net Cash remains positive at $4.5 million (now including $5.6 million in lease liabilities, under IFRS 16).

Major Drilling Group International, Inc. (MJDLF), closed Monday's trading session at $2.43915, even for the day, on 50 volume with 1 trade. The average volume for the last 3 months is 14,396 and the stock's 52-week low/high is $1.63919997/$5.03499984.

chart

PASSUR Aerospace, Inc. (PSSR)

Capital Cube, Zacks, Proactive Investors, OTC Markets, Trading View, Investors Hangout, Simply Wall St, Macroaxis, Stockopedia, Dividend Investor, Barchart, Investing.com, TipRanks, Stockwatch, MarketBeat, Journal Transcript, GuruFocus, The Street, Stockhouse, Wallet Investor, Market Screener, and PR Newswire reported earlier on PASSUR Aerospace, Inc. (PSSR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

PASSUR® Aerospace, Inc.’s mission is to improve global air traffic efficiencies through connecting the world’s aviation professionals onto a single aviation intelligence platform. The Company is a worldwide leader in digital aviation operational excellence. PASSUR provides predictive analytics and decision support technology for the aviation industry, chiefly to improve the operational performance and cash flow of airlines and the airports where they operate. Established in 1967, PASSUR Aerospace is based in Stamford, Connecticut.

PASSUR Aerospace has its new platform, Ariva™. Ariva represents the complete redesign and relaunch of the PASSUR platform, enabling customers to predict, prevent, and manage disruptions in the air and on the ground. This enables them to be even more proactive because of advanced intelligence.

PASSUR maximizes airspace, runways, and gate usage, by using predictive analytics to ascertain how airports should be configured to get the most out of their capacity. The Company helps airlines, airports, and air traffic control prioritize departures to maximize capacity and minimize delays, by helping to ensure that all three stakeholders work together with the most accurate, timely information.

The Company owns and operates the largest commercial passive radar network internationally. PASSUR provides aircraft position updates every 1 to 4.6 seconds, powering a proprietary database that is accessible in real-time, and delivers timely and accurate information and solutions through PASSUR’s industry leading algorithms and business logic included in its products.

PASSUR Aerospace’s information solutions are used at the five largest North American airlines, by more than 60 airport customers. Furthermore, these information solutions are used at the top 30 North American airports, by greater than 100 business aviation customers, and by the U.S. government.

Additionally, 53 percent of all U.S. domestic commercial flights are managed with PASSUR predictive analytics for predicted arrival times, through using years of archived data, and real-time airspace analysis. This enables airlines and airports to always be ready for the aircraft.

Recently, PASSUR® Aerospace announced that it has responded to a request from the International Air Transport Association (IATA) by developing a global portal to help the airline industry in managing the severe disruption caused by COVID-19. The ITOP Global Contingency Portal (GCP) will provide real-time sharing of critical aviation operational information worldwide.

To speed up adoption and provide much needed assistance to the air transportation community, this service is being offered at no charge. ITOP GCP is modeled on the existing IATA Tactical Operations Portal (ITOP) solution, developed and maintained by PASSUR Aerospace.

PASSUR Aerospace, Inc. (PSSR), closed Monday's trading session at $0.69, up 1.4706%, on 1,030 volume with 2 trades. The average volume for the last 3 months is 2,104 and the stock's 52-week low/high is $0.469999998/$1.70000004.

chart

BioXyTran, Inc. (BIXT)

Wallet Investor, Born2Invest, InvestorsHub, Wall Street Analyzer, last10k, Financial Buzz, Proactive Investors, Investors Hangout, Seeking Alpha, TradingView, Stockwatch, Barchart and Simply Wall St reported beforehand on BioXyTran, Inc. (BIXT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioXyTran, Inc. concentrates on developing treatments for stroke and Ischemia. An early stage pharmaceutical company, it focuses on the development, manufacture, and commercialization of different therapeutic drugs to address hypoxia in humans. The Company’s lead pharmaceutical drug candidate is BXT-25. OTCQB-listed, BioXyTran is headquartered in Newton, Massachusetts.

BioXyTran has its BXT-25 and BXT-252. The design of both drugs are to oxygenate ischemic (reduced blood flow) regions of the body and could provide sufferers valuable aid. BXT-25’s co-polymer proprietary chemical structure acts as the principal carrier of oxygen, instead of the red blood cells that are blocked by the clot.

BXT-25 construct significantly lessens methemoglobin formation and nitric oxide scavenging that may contribute to an assortment of disorders. This includes renal failure, vasoconstriction, hypertension, myocardial infarction, and also related toxicity issues. Additionally, BXT-25’s small size, around 1/5,000th that of a red blood cell, enables it to perfuse constricted, ischemic capillaries that are inaccessible to red blood cells because of clots or other obstructions.

BXT-25 is founded on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells, it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot.

In testing, BXT-25 will undergo evaluation as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. Furthermore, the product will undergo evaluation for its efficacy in treating other brain trauma issues.

The design of BioXyTran’s BXT-252 is to treat chronic wounds resulting from ischemia caused by occlusion of capillaries. BXT-252 has the same modality and physical properties as BXT-25. However, its proprietary co-polymer can improve the healing of pressure and arterial ulcers.

BioXyTran previously announced its intention to explore partnering with global drug companies looking to treat end stage Wuhan Coronavirus patients that have Acute Respiratory Distress Syndrome (ARDS).

Mr. David Platt, BioXyTran Chief Executive Officer, said, “This could be a major advancement in the treatment of end stage patients infected with the Wuhan Coronavirus. In situations like this pandemic, where resources are stretched to their limits, we are looking to develop a common sense solution to improve the mortality rate of this disease right away. Vaccines could be the answer, but they take time. We believe that potential partners will recognize that we have an immediate solution to treat acute patients with BXT-25. Even if an acute patient beats the disease down to a zero viral load they could still die from the ARDS. To fight the disease on another front, we also have the opportunity to upgrade the MDX Viewer to enable remote monitoring.”

Recently, BioXyTran announced that it signed an exclusive international licensing agreement with Dr. David Platt for the clinical development and further commercialization of a galectin inhibitor that could potentially treat COVID-19. A presentation of this technology will soon be available. With this agreement, the Company will pay a $5,000 down payment on the licensing fee to Dr. Platt by April 20, 2020. Future milestone payments of up to $4.0 million are due after; the first sample of GMP material, enrollment of the first patient in a Phase 1 trial, and an NDA approval in the U.S. Royalties will range from 15 – 25 percent based on the amount of royalties received.

BioXyTran, Inc. (BIXT), closed Monday's trading session at $0.15, up 4,900.00%, on 36,288 volume with 28 trades. The average volume for the last 3 months is 79,343 and the stock's 52-week low/high is $0.136099994/$1.95000004.

chart

TearLab Corporation (TEAR)

Zacks, Proactive Investors, MacroTrends, Wallet Investor, TipRanks, Morningstar, BioSpace, Simply Wall St, MarketBeat, Nasdaq, Market Screener, GlobeNewswire, P&T Community, Stockhouse, Investing.com, TMXmoney, Simply Wall St, Barchart and StockInvest.us reported beforehand on TearLab Corporation (TEAR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TearLab Corporation develops and markets lab-on-a-chip technologies. These technologies enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The Company’s mission is to pioneer the future of tear film diagnostics to elevate patient care. TearLab has its head office in Escondido, California. The Company lists on the OTC Markets’ OTCQB.

The TearLab Osmolarity Test is for diagnosing Dry Eye Disease. It is the first assay developed for the award-winning TearLab Osmolarity System. The TearLab Osmolarity System is a proprietary in vitro diagnostic tear testing platform. It measures tear film osmolarity for the diagnosis of dry eye disease. Furthermore, it enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.

The Company’s TearLab Osmolarity System comprises TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, and also provides a quantitative reading for the operator. TearLab is for professional in vitro diagnostic use only.

Recently, TearLab reported its consolidated financial results for Q4 and twelve months ended December 31, 2019. For the three months ended December 31, 2019, the Company’s Net Revenues were $5.5 million, down 8.3 percent from $6.0 million for the same period in 2018. TearLab’s reported Net Loss for the 2019 Q4 was roughly $1.2 million, or ($0.09) basic loss per share, versus a reported Net Loss of roughly $0.5 million, or ($0.05) basic loss per share in Q4 of 2018.

Seph Jensen, TearLab’s Chief Executive Officer, said, “We were pleased to continue the expansion of our customer base throughout 2019. We remain focused on the resubmission of our 510(k) application to secure FDA clearance of our next-generation TearLab Discovery™ System.”

TearLab Corporation (TEAR), closed Monday's trading session at $0.0431, up 69.3517%, on 551,724 volume with 72 trades. The average volume for the last 3 months is 39,241 and the stock's 52-week low/high is $0.020099999/$0.109499998.

chart

Triad Pro Innovators, Inc. (TPII)

Street Insider, OTC.Watch, Penny Stock Hub, StockReads.com, Research Pool, Investors Hangout, Green Leaf Pot Stocks, Wall Street Alerts, GlobeNewswire, TradingView, Stockhouse, Nasdaq, TipRanks, Barchart, Simply Wall St, Investors Observer, Stockopedia, Stockwatch, Dividend Investor, Investing.com, Seeking Alpha, Morningstar, OTC Markets, Wallet Investor, TMXmoney, Stock of the Week, YCharts, and InvestorsHub reported previously on Triad Pro Innovators, Inc. (TPII), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Triad Pro Innovators, Inc. operates as a renewable energy producer and storage provider. The Company owns and operates combined heat and power renewable energy facilities in California and the Western U.S. It previously went by the name Shing-Mei International, Inc. It changed its name to Triad Pro Innovators, Inc. in January of 2012. Established in 1994, Triad Pro Innovators has its corporate headquarters in La Quinta, California.

The Company’s focus is revolutionizing worldwide transportation and energy storage. It also engages in the purchase and sale of power generation equipment, and in the operation, repair, and maintenance of power generation equipment for other energy facility owners. Furthermore, Triad Pro Innovators provides energy storage solutions for residential, small business, industrial, as well as utility applications.

Triad Pro Innovators has its TriadPro eCell. This pioneering storage system replaces toxic batteries and is eco-friendly. TriadPro eCell stores electricity rapidly and charges in minutes. In addition, it requires no maintenance or routine replacement and includes a 10 year warranty.

The Company also has its SPREE (Solar Powered Renewable Electric Energy) golf carts. SPREE is the world’s first, completely solar-powered golf cart. SPREE golf carts will provide considerable reductions in energy costs for golf courses and individual golfers. The SPREE continuously tops off its maintenance-free eCell energy storage device utilizing its roof-mounted solar panel. The SPREE delivers automotive style performance with a quiet, smooth range of power. It has spacious seating, a taller roof design, and a powerful and comfortable ride.

The anticipation is that worldwide consumption of golf carts will surpass 225,000 units in 2023, in a multi-billion dollar industry, valued at U.S. $2.3 Billion of which 41 percent is projected to be the North American market. Triad Pro Innovators projects achieving roughly $70,000,000 global sales of traditional golf and people mover vehicles by the end of its third production year. The Company’s entrance and growth in this market is because of the utilization of its proprietary eCell, which will accept electrical energy using solar power or electricity.

Triad Pro Innovators, Inc. (TPII), closed Monday's trading session at $0.0195, up 195.4545%, on 52,000 volume with 6 trades. The average volume for the last 3 months is 54,818 and the stock's 52-week low/high is $0.001099999/$0.349999994.

chart

Applied Biosciences Corp. (APPB)

InvestorsHub, MarketWatch, Wallet Investor, Uptick Newswire, GuruFocus, Investors Hangout, Dividend Investor, Daily Marijuana Observer, Talk Markets, Corporate Information, Barchart, Trading View, Accesswire, Small Cap Podcast, The Street, and Stockhouse reported earlier on Applied Biosciences Corp. (APPB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Applied Biosciences Corp. is a diversified cannabinoid therapeutics company. Its focus is on the medical, bioceutical, testing and pet health industries. The Company’s emphasis is on select investment, consumer brands, and partnership opportunities in the medical, health and wellness, nutraceutical, and pet industries. Applied Biosciences has its corporate office in Beverly Hills, California.

Applied Biosciences is a leading company in the CBD and Pet health space. It is currently shipping to the majority of U.S. States and also to numerous international countries. The Company has a number of strategic partnerships now in place. It is pursuing additional partnerships and other strategic growth opportunities.

Applied Biosciences’ products include Remedi and Herbal Pet. The team at Remedi, based in Colorado, is a collaboration project of hemp and CBD industry professionals. Remedi has launched an initial line of hemp CBD infused products centered on delivery methods with proven and noticeable effects.

Herbal Pet’s focus is a new standard of care in pet health. Its product can provide safe, natural, veterinarian-recommended products directly to owners. Herbal Pet delivers premier quality cannabinoid-based nutraceuticals for cats and dogs.

Applied Biosciencespreviously announced it signed a partnership agreement with Shannon “the Cannon” Briggs, the former heavyweight boxing champion and world record-holder for the most first round knockouts. Via this new partnership, Shannon Briggs and Applied Biosciences will work together to formulate a line of athlete-focused cannabidiol (CBD) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand.

Recently, Applied Biosciences announced it retained the Emmes Group to assist with the development and execution of the Company's partnership and technology licensing initiatives and strategies. By way of the new partnership, Emmes and Applied Biosciences will work together to formulate a line of medical and scientific focused cannabidiol (CBD) based products to target the endocannabinoid system under the "Applied BioPharma" brand.

Applied Biosciences Corp. (APPB), closed Monday's trading session at $0.20, up 300.00%, on 825 volume with 4 trades. The average volume for the last 3 months is 9,148 and the stock's 52-week low/high is $0.200000002/$1.95000004.

chart

Gold Fields Limited (GFIOF)

Stock Twits, Mining Feeds, Stockhouse, 24hGold, Dividend Investor, Zacks, Street Insider, InvestorsHub, GuruFocus, last10k, MarketWatch, Junior Mining Network, The Street, Barchart, Stockwatch, StreetWise Reports, Proactive Investors, Morningstar, Equity Clock, Resource Clips, and StockChase reported earlier on Gold Fields Limited (GFIOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gold Fields Limited’s vision is to be the worldwide leader in sustainable gold mining. The Company produces gold and holds gold reserves and resources in South Africa, Ghana, Australia, and Peru. It has seven operating mines in these nations with attributable annual gold-equivalent production of about 2.2 million ounces. An internationally diversified producer of gold, Gold Fields is headquartered in Sandton, Johannesburg, South Africa. The Company lists on the OTC Markets.

Gold Fields has attributable gold Mineral Reserves of approximately 49 million ounces. The Company has gold Mineral Resources of approximately 104 million ounces. Attributable copper Mineral Reserves total 764 million pounds and Mineral Resources 4,881 million pounds.

Regarding its operations, Gold Fields has its Cerro Corona mine in Peru (Copper, Gold, Porphyry). In the West Africa region, it has its Tarkwa and Damang mines in Ghana (open pit gold mines). In the South Africa region, it has its South Deep mine. In the Australia region, Gold Fields’ assets comprise a 100 percent interest in the St Ives, Agnew, and Granny Smith mines in the Yilgarn region of Western Australia. They also include a 50 percent interest in the Gruyere project with Gold Road.

Gold Fields’ Tarkwa mine is the single largest gold producer in Ghana. It has annual production of greater than 500,000 ounces. The Tarkwa mine employs over 4,500 Ghanaians directly and by way of contractors, and close to 90 percent of its total procurement goes to Ghanaian vendors and suppliers.

Recently, Gold Fields announced normalized profit from continuing operations of US$27 million for the year ended December 2018 versus normalized profit of US$154 million for the year ended December 2017. A final dividend number 89 of 20 SA cents per share (gross) was payable on March 18, 2019. This gave a total dividend for the year ended December 2018 of 40 SA cents per share (gross).

Gold Fields Limited (GFIOF), closed Monday's trading session at $7.50, up 83.3741%, on 1,100 volume. The average volume for the last 3 months is 16 and the stock's 52-week low/high is $3.82999992/$6.09000015.

chart

Lexington Biosciences, Inc. (LXGTF)

Awesome Penny Stocks, Penny Stock Hub, MarketWatch, Morningstar, Interactive Brokers, TradingView, Dividend Investor, Tech Stock Insider, InvestorsHub, Wallet Investor, 4-Traders, and Market News Updates reported earlier on Lexington Biosciences, Inc. (LXGTF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

A medical device company, Lexington Biosciences, Inc. is developing the HeartSentry. This is a new non-invasive diagnostic device to measure and monitor cardiovascular health through assessing the function of a person's vascular endothelium. This is the vital innermost lining of a person's cardiovascular system. The Company’s aim is to become a leader in the development of clinical grade cardiovascular self-measurement solutions for home and clinical use. Lexington Biosciences has offices in Vancouver, British Columbia; and Reno, Nevada.

Lexington is engaged with the US FDA (Food and Drug Administration) and other regulatory agencies on the required product approvals for the HeartSentry. HeartSentry targets the fast-growing self-measurement medical device sector. The design of the HeartSentry unit is to use Bluetooth and Cloud technology to provide up-to-date and accurate readings of an individual’s total cardiovascular health via electronic monitoring for risk-assessment and treatment effectiveness targeting the prevention of heart attack and stroke.

HeartSentry is its flagship, and first device currently advancing to commercial deployment. The HeartSentry core technology underwent development at the University of California Berkeley over a fifteen-year research and development (R&D) period involving many research studies and product iterations resulting in a portfolio of numerous pending and issued patents licensed to Lexington Biosciences.

Lexington Biosciences announced earlier this year the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research. Lexington Biosciences’ goal is to make HeartSentry accurate, fast, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health.

Recently, Lexington Biosciences completed its first phase of clinical testing at Diablo Clinical Research. The results of the study validated safety protocols, provided Lexington with critical information for product iteration, algorithm development, and clinical testing protocol refinement in preparation for the forthcoming multi-center clinical study series.

Lexington Biosciences, Inc. (LXGTF), closed Monday's trading session at $0.067, up 73.5751%, on 1,912 volume with 5 trades. The average volume for the last 3 months is 7,287 and the stock's 52-week low/high is $0.009999999/$0.598999977.

chart

China YCT International Group, Inc. (CYIG)

SquawkBoxStocks, Penny Pick Finders, TerrificPennyStocks, Breaking Bulls, AwesomeStocks, PennyStocks24, Chatter Box Stocks, MyBestStockAlerts, Buzz Stocks, PennyStockCrowd, Marquee Penny Stocks, Penny Stock Rumble, PennyStocksV2, and Planet Pennies reported earlier on China YCT International Group, Inc. (CYIG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

China YCT International Group, Inc is a developer, manufacturer, and distributor of traditional Chinese medicines (TCM). A biotechnology company, it mainly concentrates on producing medicines and selling organic healthcare products. In addition, China YCT is a significant player in the Acer Truncatum oil business. The Company anticipates that this will be a billion-dollar market in the near future.

China YCT International Group has its head office in Sishui County, Shandong Province, China. It lists on the OTC Markets Group’s OTCQB.

The Company engages in developing, manufacturing, and selling its own TCM’s made primarily from ginseng extract, manufacturing and distributing acertruncatumbunge seed oils, and distributing health care supplement products in China.

China YCT International Group announced in May 2017 that it signed an agreement to purchase the Acer Truncatum business from Shandong YCT Group Co. Ltd. The expectation is that this new business will increase sales by a billion U.S. dollars for China YCT in the next 5 years.

Acer Truncatum is a kind of maple. It has 300 species around the world. Acer Truncatum is only available in China.

The Acer Truncatum oil contains 5.8 percent of nervonic acid. Acer Truncatum is contained in plants, and nervonic acid can undergo extraction from these very economically. After more than 40 years’ research and experiments, the Chinese government approved Acer Truncatum oil as general wood food oil that can be used as a general food oil, such as soybean, corn, olive, as well as other food oils.

Mr. Yan Tinghe, China YCT International Group's Chief Executive Officer, said, "The Company's next business goal is to become a leading enterprise in research, cultivation, and production in the domestic and international market for acertruncatum woody edible oils."

China YCT International Group, Inc. (CYIG), closed Monday's trading session at $0.11, up 80.3279%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 861 and the stock's 52-week low/high is $0.061/$0.584999978.

chart

The QualityStocks Company Corner

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the additive manufacturing industry, today announced its appointment of Mark K. Ruport as president and chief executive officer. According to the update, Ruport will continue to serve as a member of the Board of Directors and, as part of the transition, John Rice has stepped aside from his position as president and CEO and will continue in his role as the non-executive chairman of the Board of Directors of Sigma Labs. To view the full press release, visit http://nnw.fm/Pc5Vb

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Monday's trading session at $2.38, up 4.5281%, on 153,184 volume with 501 trades. The average volume for the last 3 months is 250,972 and the stock's 52-week low/high is $1.97000002/$17.00.

Recent News

chart

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF)

The QualityStocks Daily Newsletter would like to spotlight Champignon Brands Inc. (CSE: SHRM).

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced it has advanced its North American new clinical entity (“NCE”) expansion stratagem via the formation of a dedicated planning committee (the “Committee”). To view the full press release, visit http://cnw.fm/Rns1B

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF) is a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements. Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon’s expanding portfolio is crafted with the health-conscious consumer in mind.

Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

Brands

Champignon’s mushroom-derived consumer packaged goods (CPGs) portfolio includes its flagship brand, Vitality Superteas. Each carefully curated Vitality Supertea formulation was developed with the intent of helping individuals enhance and enrich their wellbeing one cup of mushroom-infused tea at a time.

Also in the portfolio are Nourish Force Supertea, a blend of Reishi Ryobus Tea Mix; Mighty Recharge Supertea, created with Lions Mane Tropical Green Ginseng Tea Mix; and Brain Enhance Supertea, a blend of Cordycep Hibiscus and Berries Tea Mix – all of which are formulated with organic ingredients and chosen for their ability to provide unique health and performance benefits.

Champignon’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom vertical space with a selection of mushroom-infused teas and accessories.

Functional Mushroom Market

Demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024 (ResearchandMarkets), with Europe seen as the fastest growth leader.

According to the market study, in highest demand are products infused with Reishi – a traditional Chinese medicine also known as the “Elixer of Life” and “Mushroom of Immortality – Lions Mane and Cordyceps, followed by other types of medicinal mushrooms.

Advances in Legalization

Legalization of psychedelics for use in medicine is gaining momentum across the United States. Denver, Colorado, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for legalization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7 million people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
A renaissance in alternative medicines is emerging, and Champignon has set in motion its strategy to become a key player.

2020 Stealth IP Strategy

Champignon plans to biosynthesize psilocybin within the first three months of conducting laboratory experiments, with the objective of achieving optimized and scaled production of pharmaceutical-grade psilocybin for deployment in clinical settings. This strategy includes:

  • Alternative medicine (psilocybin) IP aggregation
  • Development of cGMP formulations of bioactive compounds extracted from plants and Fungi
  • Drafting of benchmark SOPs (Standard Operating Procedures)
  • Patient aggregation, focusing on veterans

Defining a New Asset Class: Psychedelic-Inspired Medicines

In the third quarter of 2020, Champignon – through clinical trials, a compelling IP portfolio and clinical pipeline and drug development platform – plans to advance its pursuit of treatments underpinned by psychedelic substances. This strategy is broken down into two ties:

  • Non-Hallucinogenic Medicines
    • Microdosing Psilocybin/LSD
    • MDMA, commonly known as ecstasy
  • Hallucinogenic Medicines
    • Psilocybin high dose
    • LSD high dose

Partnerships

Companies worldwide are beginning to incorporate functional mushrooms into their product offerings, taking advantage of growing consumer awareness of known health benefits of the ingredients found in mushrooms.

Champignon in November 2019 entered into a distribution partnership with Eurolife Brands Inc. (CSE: EURO), a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics. Under the agreement, Champignon’s branded products are integrated into Eurolife’s e-commerce platform, along with potential distribution opportunities in select brick-and-mortar retail locations in Europe.

Champignon also has an R&D/production formulation agreement with Drip Coffee Social Ltd., located in Nanaimo, British Columbia, which calls for the infusion of Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.

Leadership

Gareth Birdsall, CEO, Corporate Secretary and Director
Gareth Birdsall has more than seven years of experience working in diverse agricultural roles such as the cultivation of various fungi, in particular Cordycepes, Reishi, Lions Mane and Chaga. He is an attendee of the British Columbia Institute of Technology, studying marketing management and finance.

Steven Brohman, CPA, CFO
Steven Brohman has more than 10 years of experience working in a variety of roles with public and private companies. He has had extensive training in the audit of publicly traded companies on the TXS, TSX Venture Exchange and OTC markets, and serves as CFO and director of various public and private companies. Brohman has a bachelor’s degree of business administration and obtained his Chartered Professional Accountant designation.

Jerry Habuda, Director
Jerry Habuda brings to Champignon over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

Champignon Brands Inc. (CSE: SHRMF), closed Monday's trading session at $0.75, up 6.99%, on 366,699 volume with 407 trades. The average volume for the last 3 months is 155,086 and the stock's 52-week low/high is $0.221/$0.797500014.

Recent News

chart

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA)

The QualityStocks Daily Newsletter would like to spotlight PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA).

PowerBand Solutions Inc. (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) has launched a new cloud-based platform that lets people buy and sell cars and trucks with never-seen-before simplicity, speed, and cost-efficiency. This development is proving pivotal during the Covid-19 pandemic, as automakers and dealers take a long, hard look at innovations to allow consumers to buy, sell, trade and lease on-line. Also today, NetworkNewsWire released a report on the company detailing how PWWBF today announced its launch of an innovative digital advertising campaign to offer its virtual-transaction platform to consumers and automotive dealers across the United States. To view the full press release, visit http://nnw.fm/xc2SK

A Better Way to Connect and Acquire Vehicles

PowerBand’s mission is to create an online, consumer-directed marketplace that streamlines the interactions among all participants in the automotive industry. It transforms today’s antiquated business model with speed, transparency, access to information and ease of use for consumers and dealers.

Consumers can easily connect with new sources to buy vehicles, network with motivated buyers and sellers, maximize their trade-in values, improve their customer experience. PowerBand’s standardized system and transaction process also increase efficiencies and benefits with hands-on, process-driven, in-store training and support.

Through internal development, acquisitions, joint ventures and strategic partnerships, PowerBand is developing solutions for consumers, dealers, manufacturers, commercial customers and lenders that are poised to transform the trillion-dollar U.S. automotive industry.

The PowerBand Auto Platform

PowerBand’s transaction platform was developed by a team of experienced automotive, technology and finance experts, and has been refined through years of operational experience. Built on the core belief that the consumer prefers to primarily conduct automotive transactions online and avoid interactions with unnecessary middlemen, PowerBand’s product solutions include:

  • Leasing: PowerBand is currently licensed in 33 U.S. states via a majority interest in MUSA Auto Finance LLC, an advanced online leasing technology platform that has transformed the new and used vehicle leasing industry. A partnership with Tesla was recently finalized, making MUSA the only approved, non-captive lease partner for Tesla in the U.S.
  • Inventory and Financing: A partnership with RouteOne LLC, a leading financial platform founded in 2002 by Ally Financial, Ford Motor Credit Co., TD Auto Finance and Toyota Financial Services, allows access to a network of more than 18,000 dealerships and 1,400 financing sources.
  • Auction Platform: PowerBand and its joint-venture partner, D2D Auto Auctions, are developing a direct consumer-to-dealer and a consumer-to-consumer automotive portal, which will provide an innovative alternative to physical dealership and auction locations.
  • LiveNet Auction: An online platform portal that allows dealers to create instant live vehicle auctions to a vast network of the industry’s top used vehicle buyers.
  • MarketPlace Auction: An online listing auction site for buying and selling automotive inventory – ideal for dealers, fleet, OEM and rental companies.
  • Used Vehicle Inspections: An LOI agreement with TÜV NORD Mobility Inc., a German-based global leader in vehicle inspections operating in more than 70 countries, will provide the most comprehensive, certified vehicle inspection reports available in North America. Appointments booked within the platform can be performed nearly anywhere.
  • Product Development: PowerBand’s comprehensive consumer solution, Driveaway, will be a fully transactional consumer marketplace where dealers and consumers can buy, sell, trade-in and finance vehicles, often in seconds, from the comfort of their home.

Automotive’s Growing Markets

The automotive dealership and commercial fleet vehicle auction industry is a $100-billion sector with more than 40 million used vehicles transacted in the U.S. each year. Of those, ten million are sold through auctions. From 2013 to 2017, the growth of online-only auctions far outpaced physical auctions, growing at a 33% compound annual growth rate compared to 2% CAGR at physical auctions.

Automotive leasing is another large, growing and fragmented market, generating approximately $120-billion in annual revenue. As a percentage of vehicle sales, leasing reached 30% in 2018, up from 21% in 2012, and is seen as a substantial opportunity for PowerBand and MUSA Auto Finance. Using proprietary technology and by focusing on high-quality, credit-worthy customers, MUSA grew its automotive lease originations to $182 million.

Disrupting Auto Leasing with MUSA

Legacy solutions are complicated, expensive and slow at processing leases. MUSA’s first-of-its-kind technology platform eliminates third-party decisions and the human capital required in the underwriting process. MUSA’s platform navigates the entire customer experience – underwriting, funding and the delivery process – within minutes. Leases can be approved in seconds.

PowerBand’s acquisition of MUSA brings together two leading-edge companies with the vision to become a one-stop platform for the entire vehicle purchase lifecycle.

Experienced Leadership

PowerBand is led by a collection of automotive veterans with a passion to collectively and positively impact the industry.

  • Kelly Jennings, president and CEO, is the founder of PowerBand Solutions and a franchise dealer owner/operator with more than 27 years of automotive experience. Jennings received General Motor’s Triple Crown Award, Ford Motor Company President’s Award and Honda Canada’s Excellence Award.
  • Darrin Swenson, COO of PowerBand and D2D Auto Auctions/Hunt Automotive Group, has more than 25 years of automotive/auction experience.
  • Jeff Morgan, CEO MUSA, holds over 25 years of experience in the auto finance sector.

 

PowerBand Solutions Inc. (OTCQB: PWWBF), closed Monday's trading session at $0.0984, up 3.3613%, on 500 volume with 1 trade. The average volume for the last 3 months is 29,800 and the stock's 52-week low/high is $0.038600001/$0.230000004.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) (the “Company”), formerly Sharing Services Inc., announces the appointment of Chan Heng Fai Ambrose to serve on the Company’s board of directors (the “Board”) as a Class II Director to serve until the annual meeting of shareholders in 2023, or until his successor is elected and qualified. This appointment fills a vacancy created by the recently announced resignation of Kip H. Allison from the Board.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Monday's trading session at $0.084, up 7.0064%, on 75,506 volume with 6 trades. The average volume for the last 3 months is 710,931 and the stock's 52-week low/high is $0.0215/$0.25.

Recent News

chart

The Movie Studio Inc. (OTC: MVES)

The QualityStocks Daily Newsletter would like to spotlight The Movie Studio Inc. (OTC: MVES).

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on delivering video on demand (VOD) services leveraging a unique business model built to capitalize on the worldwide demand for online film content. MVES is providing subscription-based, over the top (OTT) services delivered through a wireless internet connection to the end user’s devices, such as smartphones, tablets and laptops.

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on acquiring, developing, producing and distributing independent motion picture content for worldwide consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales and various media devices. The company is currently engaged in establishing its own OTT VOD platform to integrate both its own and aggregated feature film projects, television programming and other media intellectual properties. The Movie Studio is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and the company intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution.

The company has launched The Movie Studio App on Google Play and the App Store, enabling users to both view the company’s content and potentially become part of it. The app is in the completion stage, and The Movie Studio is conducting its final beta test of the app’s unique “audition submission” function, leveraging the company’s “Watch Our Movies, Be in Our Movies!” content platform and “Everyone’s a Star” campaign, which will be marketed via social media. Using the app, subscribers can upload a thumbnail photo of themselves along with a selfie video audition submission that showcases them reading character dialog. Audition submissions will then be reviewed by producers for possible participation of the auditionee in upcoming feature films.

The audition submission function provides the subscriber the ability to disrupt traditional motion picture casting and management, enabling access to participation in The Movie Studio’s independent motion picture and media content. At the same time, for the company this significantly reduces capital expenditures associated with those traditional media mechanisms. The Movie Studio’s unique business model capitalizes on the global demand for film content through the production and distribution of its own films while also providing opportunities for direct viewer involvement in its content.

The company operates using a growth-by-acquisition strategy that includes:

  • Purchasing legacy film libraries.
  • Upgrading acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the internet.
  • Strategic partnerships and media content alignment with other OTT platforms and cross-collateralization of leverageable media assets for worldwide distribution.
  • Producing micro-budget motion picture content with substantial production value utilizing new 4K technology and the company’s extensive legacy resources and unique production process, thereby significantly reducing capital expenditures while allowing for the potential of significant return on investment (ROI) with one successful production.
  • Controlling its revenue streams through server-driven geo-fracturing global territories and its own OTT platform.

Currently, The Movie Studio is producing three upcoming feature films: “Cause and Effect,” “The Last Warhead” and “PEGASUS” — all with completed electronic press kits and pitch decks and fully produced motion picture-quality trailers ready for talent, distribution and financial integration.

The company has been successful in producing, casting and distributing its films on major SVOD platforms without recognizable stars, which reduces capital expenditures. However, The Movie Studio intends to integrate recognizable stars into the productions at value propositions either pre- or post-completion of the intellectual property.

Through successful beta testing, The Movie Studio has monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The company’s proposed server-based model will provide licensing payment from global territories without third-party distribution fees, which have traditionally been as high as 35%.

Founded in 1961 and formerly known as Destination Television, Inc., the company changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio is headquartered in Fort Lauderdale, Florida.

Cord-Cutting Creates Opportunity for VOD Players

Consumers are no longer content waiting for their favorite programming to come on the air – they expect instant streaming access where and how they want it. This has led to increased “cord cutting,” with consumers severing ties with their traditional pay TV providers in favor of digital streaming services.

With the advent of smart TVs with app integration, consumers can now watch what they want to watch when they want to watch it, fracturing traditional cable bundling mechanisms.

With pay TV usage steadily declining – satellite and cable TV businesses in the United States lost approximately 6 million customers in 2019 alone – streaming platforms are poised to potentially replace traditional pay TV distribution models altogether. Approximately 12,000 U.S. consumers are cutting the cord every day.

As this shift in media delivery continues and as digital devices become more sophisticated and bandwidth increases, VOD platforms have the potential to scale significantly. The Hollywood “streaming wars” of recent years have created an environment in which smaller competitors, like The Movie Studio, are able to emerge as major brands.

The Movie Studio Inc. (OTC: MVES), closed Monday's trading session at $0.01095, even for the day, on 80 volume with 2 trades. The average volume for the last 3 months is 56,391 and the stock's 52-week low/high is $0.0063/$0.07.

Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group, Inc. (NASDAQ: MEDS), an integrated telehealth, drug procurement, delivery and online healthcare marketplace, today reported its financial results for the first quarter ended March 31, 2020. Among the highlights, Trxade reported a 46% increase in Q1 2020 revenues to $2.2 million and 44% increase in net income to $0.2 million. To view the full press release, visit http://nnw.fm/i4CD2

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Monday's trading session at $7.585, off by 4.471%, on 110,542 volume with 575 trades. The average volume for the last 3 months is 140,057 and the stock's 52-week low/high is $2.70000004/$11.6000003.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was recently covered by leading publisher Small Caps Daily concerning their recently announced accretive acquisitions which position the Company to expand into several lucrative markets.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Monday's trading session at $3.45, off by 3.0899%, on 7,750 volume with 43 trades. The average volume for the last 3 months is 11,161 and the stock's 52-week low/high is $0.600600004/$3.8499999.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today reported results for the year ended December 31, 2019 and the three months ended March 31, 2020. In addition, the company announced the rebrand of its investor intelligence platform, SRAX IR, to Sequire, with the new brand reinforcing its continued focus on innovation and strides for uniqueness in the marketplace. To view the full press release, visit http://nnw.fm/7h5TE and http://nnw.fm/zqv1Q.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Monday's trading session at $2.00, off by 9.0909%, on 103,073 volume with 358 trades. The average volume for the last 3 months is 54,401 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

chart

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE: UUUU) (TSX: EFR) on Friday reported its financial results for the quarter ended March 31, 2020. According to the update, the Company's quarterly report on Form 10-Q has been filed with the U.S. Securities and Exchange Commission ("SEC") and may be viewed on the Electronic Document Gathering and Retrieval System ("EDGAR") at www.sec.gov/edgar.shtml, on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on the Company's website. To view the full press release, visit http://nnw.fm/r1hvW

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

 

Energy Fuels Inc. (UUUU), closed Monday's trading session at $1.69, off by 6.1111%, on 3,315,497 volume with 8,644 trades. The average volume for the last 3 months is 1,787,696 and the stock's 52-week low/high is $0.779999971/$3.31999993.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progress with Oncoprex(TM), its lead drug candidate with an initial targeted indication for non-small cell lung cancer (“NSCLC”), its license agreement for a diabetes gene therapy drug candidate, as well as other operational and business achievements. To view the full press release, visit http://nnw.fm/bm9L2

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Monday's trading session at $2.31, up 1.7621%, on 1,236,872 volume with 2,871 trades. The average volume for the last 3 months is 5,619,525 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International (NASDAQ: YGYI), together with its wholly owned subsidiary, Khrysos Industries, Inc., today announced the launch of a web interface dedicated for the sale of the company's new line of hand sanitizers. The landing page (www.Khrysos-HandSanitizer.com) targets both businesses and consumers and can be accessed for immediate purchase. To view the full press release, visit http://cnw.fm/anO4X

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Monday's trading session at $1.71, up 8.2278%, on 1,286,317 volume with 3,973 trades. The average volume for the last 3 months is 869,261 and the stock's 52-week low/high is $0.610000014/$6.76999998.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF) today announced its partnership with TASSTA, a global mission critical push-to-talk (“MCPTT”) software provider and end-to-end solution for critical communications. According to the update, TASSTA has integrated its MCPTT application across the portfolio of Siyata’s in-vehicle (“UV350” and “CP250”) communications devices, and the initial opportunities to work together are in Southeast Asia. To view the full press release, visit http://nnw.fm/QEd9s

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Monday's trading session at $0.1101, up 0.090909%, on 549,100 volume with 39 trades. The average volume for the last 3 months is 188,574 and the stock's 52-week low/high is $0.086400002/$0.392500013.

Recent News

chart

Xalles Holdings Inc. (OTC: XALL)

The QualityStocks Daily Newsletter would like to spotlight Xalles Holdings Inc. (OTC: XALL).

Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing technology and financial services solutions, today announced its execution of a share purchase agreement to acquire 100% of Intel365, Inc., a Georgia based innovative background screening services company. Under the agreement, Xalles Technology Inc., a wholly owned subsidiary of Xalles Holdings Inc., will acquire all of the common shares of Intel365, Inc. Intel365 is based in Cumming, Georgia, part of the metropolitan Atlanta area, with a vision to provide technology and services in the areas of corporate intelligence, employment screening and technology due diligence. To view the full press release, visit http://ccw.fm/U3gw6

Xalles Holdings Inc. (OTC: XALL) is a fintech holding company leveraging blockchain and other technologies for e-commerce, payments, financial reconciliation, and payment auditing solutions. The company actively seeks acquisition targets with strong management teams and business models, large total attainable markets, and lucrative exit opportunities in which to invest and accelerate growth.

Operations

The common element to all acquired entities and projects is a business model that involves setting up a payment or financial transaction “toll gate,” thereby creating a recurring revenue stream.

Xalles’ business plan focuses on consumer, business and government-oriented payment and financial reconciliation transactions. Combining the blockchain decentralized financial ledger platform with the company’s existing X2X transaction reconciliation system design, Xalles is building technology that supports payment audits, exchanges, and new business models and opportunities worldwide. Xalles will launch new services card and mobile payment and rewards systems, and will expand the technology offerings for referral marketing and e-commerce engines.

Subsidiaries
(all current subsidiaries are wholly owned)

  • Xalles Holdings
    Raise capital for fintech accelerator program acquisitions, provide management, administrative, finance and marketing support to all subsidiary companies
  • Xalles Capital
    Management support of investment consortiums, direct investment into funds or projects, and management of investments
  • Xalles Limited
    Design and market new X2X solutions; acquire U.S Government transportation post-payment audit business through GSA schedule and expand to non-transportation payment auditing
  • Xalles Technology
    Technical development of the X2X blockchain systems
  • Xalles Financial Services
    Consumer and small business financial service offerings
  • Co-Owners Rewards
    Stock-based rewards system for payments cards and financial services
  • Amazing Living Enterprises
    Affiliate program and e-commerce platform for enhancing financial lives
  • Global Savings Network
    Not-for-profit fundraising system with consumer discounts at local merchants

X2X Solutions

Xalles provides payment and financial transaction management solutions through the company’s proprietary blockchain-based X2X technology. The X2X solution includes the Investment and Financing System (IFS), which supports complex investment structures, assists international investment consortia, and provides links to Xalles’ Financial Transaction Reconciliation (FTR) solution. FTR supports complex financial ecosystems, making it easier for parties to exchange products, services, grants and government incentives, and assists “Exchange Managers” with liquidity and auditability. X2X also supports the Xalles pre- and post-payment auditing services.

Plans for 2020

  • Xalles expects to announce new acquisitions of fintech growth firms.
  • The company’s strategy for 2020 includes revamping its consumer Commerce platform, to bring in the best elements of local and online shopping with payment tools and a unique rewards program.
  • Xalles Financial Services expects to expand its cryptocurrency related service offerings through partnerships, acquisitions and organic growth
  • The Blockchain based X2X system will continue to be enhanced to deliver new financial reconciliation services to large enterprises and governments.

Xalles Holdings Inc. (OTC: XALL), closed Monday's trading session at $0.0085, up 13.3333%, on 26,344,211 volume with 613 trades. The average volume for the last 3 months is 5,113,334 and the stock's 52-week low/high is $0.000699999/$0.021029999.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its entry into definitive agreements with certain qualified investors for the sale of 8,978,260 shares ("Shares") of its common stock along with common stock purchase warrants ("Warrants") to purchase up to 8,978,260 shares of its common stock in a private placement (collectively the "Offering") for gross proceeds of over US$2 million. To view the full press release, visit http://cnw.fm/oEv0l

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Monday's trading session at $0.2827, off by 0.106007%, on 27,477 volume with 23 trades. The average volume for the last 3 months is 106,935 and the stock's 52-week low/high is $0.229499995/$1.07000005.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.